Abstract
This report describes two patients with multidrug resistant tuberculosis who were successfully treated with the addition of amoxicillin-clavulanic acid to second-line drugs. Mycobacterium tuberculosis possesses a beta-lactamase contributing to its resistance to beta-lactam antibiotics. The combination of clavulanic acid, a beta-lactamase inhibitor, and amoxicillin has been shown bactericidal for M tuberculosis in vitro. These data suggest that resistant tuberculosis may warrant a trial of treatment including amoxicillin-clavulanic acid.
MeSH terms
-
Adult
-
Amoxicillin / administration & dosage
-
Amoxicillin / therapeutic use*
-
Antitubercular Agents / therapeutic use
-
Clavulanic Acid
-
Clavulanic Acids / administration & dosage
-
Clavulanic Acids / therapeutic use*
-
Drug Combinations
-
Drug Resistance, Microbial
-
Drug Therapy, Combination
-
Female
-
Humans
-
Male
-
Mycobacterium tuberculosis / drug effects*
-
Tuberculosis, Pulmonary / drug therapy*
-
beta-Lactamase Inhibitors*
Substances
-
Antitubercular Agents
-
Clavulanic Acids
-
Drug Combinations
-
beta-Lactamase Inhibitors
-
Clavulanic Acid
-
Amoxicillin